Around 70% of patients with ovarian cancer are likely to experience recurrence, according to the Ovarian Cancer Research Alliance. Studies show that the stage of cancer strongly influences the recurrence risk, with Stage 3 and Stage 4 ovarian cancer reported to demonstrate a 70-90% and 90-95% chance of recurrence, respectively. Advanced treatments such as antibody-drug conjugates (ADCs) and PARP inhibitors are increasingly showing positive outcomes in clinical trials. Further, accelerated approvals by regulatory bodies and the growing focus on the development of targeted therapies are poised to aid in pipeline expansion for advanced recurrent ovarian cancer in the coming years.
Major companies involved in the advanced recurrent ovarian cancer pipeline drugs market include BioMimetix JV, LLC and Valerio Therapeutics, among others.
Leading drugs currently under the pipeline include BMX-001 + Paclitaxel and SSGJ-707, among others.
The rising incidence rates of ovarian cancer along with the growing R&D investment in new treatments by pharmaceutical companies are anticipated to positively impact the pipeline landscape.
The Advanced Recurrent Ovarian Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into advanced recurrent ovarian cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced recurrent ovarian cancer. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The advanced recurrent ovarian cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from advanced recurrent ovarian cancer.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to advanced recurrent ovarian cancer.
The recurrence rate for ovarian cancer is estimated to be around 80%. It is observed that cancer has a higher likelihood of recurrence if the disease is fast-growing or has reached an advanced stage at the time of diagnosis. Recurrence of ovarian cancer can occur anytime, from weeks to years after treatment. In cases of highly chemotherapy-resistant ovarian cancer, recurrence can even happen during the weeks post-treatment.
Platinum-based chemotherapies are commonly used for the treatment of advanced recurrent ovarian cancer. PARP inhibitors like olaparib, niraparib, and rucaparib are reported to show efficacy in patients with BRCA mutations. Moreover, FDA-approved Elahere (mirvetuximab soravtansine) is a promising therapy for treatment-resistant cases. Robust research efforts focused on exploring novel treatments, including vaccines aimed at preventing recurrence and innovative therapies like natural killer (NK) cell treatments, are expected to accelerate the advancement of the drug pipeline in the near future.
This section of the report covers the analysis of advanced recurrent ovarian cancer drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total clinical trials for advanced recurrent ovarian cancer.
The drug molecule categories covered under the advanced recurrent ovarian cancer pipeline analysis include oligonucleotide, peptide, and small molecule. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for advanced recurrent ovarian cancer.
The EMR report for the advanced recurrent ovarian cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in advanced recurrent ovarian cancer clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by BioMimetix JV, LLC, the objective of this Phase I/II clinical trial is to investigate the efficacy and safety of the combination therapy Paclitaxel (Taxol) and BMX-001 in an estimated 27 adult patients with advanced, recurrent, metastatic ovarian or endometrial cancer.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is conducting a Phase II clinical study aimed at evaluating the antitumor activity, safety, and tolerability of SSGJ-707 for the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The interventional study has enrolled about 80 subjects and is expected to be completed by August 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Advanced Recurrent Ovarian Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for advanced recurrent ovarian cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within advanced recurrent ovarian cancer pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share